Skip to main content
Log in

Is the information provided by amino acid PET radiopharmaceuticals clinically equivalent in gliomas?

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncol. 2016;18:1199–208.

    Article  PubMed  Google Scholar 

  2. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol (Berl). 2016;131:803–20.

    Article  Google Scholar 

  3. Grosu A-L, Weber WA, Riedel E, Jeremic B, Nieder C, Franz M, et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:64–74.

    Article  CAS  PubMed  Google Scholar 

  4. Okubo S, Zhen H-N, Kawai N, Nishiyama Y, Haba R, Tamiya T. Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J Neuro-Oncol. 2010;99:217–25.

    Article  CAS  Google Scholar 

  5. Ishiwata K, Kubota K, Murakami M, Kubota R, Sasaki T, Ishii S, et al. Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med Off Publ Soc Nucl Med. 1993;34:1936–43.

    CAS  Google Scholar 

  6. Vander Borght T, Asenbaum S, Bartenstein P, Halldin C, Kapucu O, Van Laere K, et al. EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging. 2006;33:1374–80.

    Article  CAS  PubMed  Google Scholar 

  7. Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Långström B, et al. Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. Cancer. 2001;92:1541–9.

    Article  CAS  PubMed  Google Scholar 

  8. Moulin-Romsée G, D’Hondt E, de Groot T, Goffin J, Sciot R, Mortelmans L, et al. Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine? Eur J Nucl Med Mol Imaging. 2007;34:2082–7.

    Article  PubMed  Google Scholar 

  9. Janvier L, Olivier P, Blonski M, Morel O, Vignaud J-M, Karcher G, et al. Correlation of SUV-derived indices with Tumoral aggressiveness of gliomas in static 18F-FDOPA PET: use in clinical practice. Clin Nucl Med. 2015;40:e429–35.

    Article  PubMed  Google Scholar 

  10. Villani V, Carapella CM, Chiaravalloti A, Terrenato I, Piludu F, Vidiri A, et al. The role of PET [18F]FDOPA in evaluating low-grade glioma. Anticancer Res. 2015;35:5117–22.

    CAS  PubMed  Google Scholar 

  11. Bette S, Gempt J, Delbridge C, Kirschke JS, Schlegel J, Foerster S, et al. Prognostic value of O-(2-[18F]-Fluoroethyl)-L-tyrosine-positron emission tomography imaging for histopathologic characteristics and progression-free survival in patients with low-grade glioma. World Neurosurg. 2016;89:230–9.

    Article  PubMed  Google Scholar 

  12. Lopci E, Riva M, Olivari L, Raneri F, Soffietti R, Piccardo A, et al. Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. Eur. J. Nucl. Med. Mol. Imaging. 2017

  13. Verger A, Metellus P, Sala Q, Colin C, Bialecki E, Taieb D, et al. IDH mutation is paradoxically associated with higher 18F–FDOPA PET uptake in diffuse grade II and grade III gliomas. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2017 [cited 2017 Mar 14]; Available from: http://link.springer.com/10.1007/s00259-017-3668-6

  14. Manabe O, Hattori N, Yamaguchi S, Hirata K, Kobayashi K, Terasaka S, et al. Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging. Eur J Nucl Med Mol Imaging. 2015;42:896–904.

    Article  CAS  PubMed  Google Scholar 

  15. Becherer A, Karanikas G, Szabó M, Zettinig G, Asenbaum S, Marosi C, et al. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging. 2003;30:1561–7.

    Article  CAS  PubMed  Google Scholar 

  16. Metellus P, Colin C, Taieb D, Guedj E, Nanni-Metellus I, de Paula AM, et al. IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. J Neuro-Oncol. 2011;105:591–600.

    Article  CAS  Google Scholar 

  17. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483:474–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Oizel K, Gratas C, Nadaradjane A, Oliver L, Vallette FM, Pecqueur C. D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH. Cell Death Dis. 2015;6:e1704.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (Berl). 2007;114:97–109.

    Article  Google Scholar 

  20. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A. 2011;108:3270–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Grassian AR, Parker SJ, Davidson SM, Divakaruni AS, Green CR, Zhang X, et al. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Res. 2014;74:3317–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A. Verger.

Ethics declarations

Funding

This work has been carried out in the framework of DHU-Imaging thanks to the support of the A*MIDEX project (n° ANR-11-IDEX-0001-02) funded by the « Investissements d’Avenir » French Government program, managed by the French National Research Agency (ANR) and INCa-DGOS-Inserm 6038 Grant (SIRIC Marseille Glioma program).

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Verger, A., Taieb, D. & Guedj, E. Is the information provided by amino acid PET radiopharmaceuticals clinically equivalent in gliomas?. Eur J Nucl Med Mol Imaging 44, 1408–1410 (2017). https://doi.org/10.1007/s00259-017-3710-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-017-3710-8

Keywords

Navigation